LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Merit Medical Systems to Present at the J.P. Morgan 42nd Annual Healthcare Conference

January 03, 2024 | Last Trade: US$101.83 0.63 0.62

SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. A live audio webcast of the conference presentation will be available on the investor section of the Merit Medical website www.merit.com.

“Merit is honored to be amongst this remarkable group of companies represented at the conference,” said Mr. Lampropoulos. “We are excited to share with this distinguished audience our continuing mission of product innovation to improve patients’ lives.”

ABOUT MERIT MEDICAL

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide. 

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS 

PR/Media Inquiries 
Sarah Comstock 
Merit Medical 
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it. 

INVESTOR INQUIRIES 
Mike Piccinino, CFA, IRC 
Westwicke - ICR 
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB